HHS National Institute of Allergy & Infectious Diseases: NIH Study Finds Tecovirimat Was Safe But Did Not Improve Mpox Resolution or Pain
December 11, 2024
December 11, 2024
WASHINGTON, Dec. 11 (TNSres) -- The U.S. Department of Health and Human Services National Institute of Allergy and Infectious Diseases issued the following news release:
* * *
Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak
* * *
The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing seve . . .
* * *
Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak
* * *
The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing seve . . .